Investigator initiated trials (IIT) continue to play a critical role for pharma and medical device companies.  IITs further research in areas of interest and help develop insights into product effectiveness with patient populations.  In addition, more efforts are incorporating real-world evidence (RWE) into strategic planning to meet regulatory requirements and support the value propositions for new and existing products.

Stephen Rothenberg, J.D. and Michael Abrams, M.A. provide insight on how incorporating IIT/RWE strategy will help drive market differentiation and value in Integrating RWE into Investigator Initiated Trials published by Pharmaceutical Compliance Monitor.